Immix Biopharma, Inc. (IMMX) SEC Filings & Earnings Calls

Dilution from equity offering.

“Underwriting Agreement for offering of shares.”

Clinical trial results are interim; final readout and BLA submission planned for mid-2027, with regulatory and commercial risks.

“NEXICART-2 final readout and BLA submission planned in mid-2027” · word for word

Going concern risk mitigated by cash raise

“We believe that our existing cash, cash equivalents, and short-term investments as of June 30, 2026 will enable us to fund our operating expenses and capital expenditure requirements for at least the next 12 months from the filing of our Quarterly Report on Form 10-Q.” · word for word

Clinical trial risk

“Products developed by the Company require approvals from the U.S. Food and Drug Administration ("FDA") or other international regulatory agencies prior to commercial sales. There can be no assurance that the Company's research and development will be successfully completed.” · word for word

Dilution risk

“Weighted average shares outstanding increased from 29.8M (H1 2025) to 59.6M (H1 2026), reflecting significant equity issuance.”

No material risk; termination of short-tenure employee with no business impact.

“Management believes there is no material effect on the business.” · word for word

Clinical trial risk: interim data may differ from final results; regulatory disagreement possible.

“Interim data from clinical trials are subject to various risks... final results may be materially different” · word for word

Small sample size (20 patients); results may not be reproducible in larger trials.

“first 20 patients in NEXICART-2” · word for word

Dilution risk: ~16.8M new shares issued; significant dilution for existing shareholders.

“aggregate of 16,778,524 shares of its common stock” · word for word

Cash burn risk: proceeds will fund operations but no revenue disclosed; pre-revenue biotech.

“net proceeds... expected to be approximately $140.65 million”

Clinical-stage biotech with no approved products

“The Company is a clinical-stage biopharmaceutical company focused on developing cell therapies in AL Amyloidosis and select immune-mediated diseases.” · word for word

History of losses and accumulated deficit

“The Company had a net loss of $10.1 million for the three months ended March 31, 2026 and $29.4 million for the year ended December 31, 2025 and an accumulated deficit of $114.5 million as of March 31, 2026.” · word for word

Dependence on additional financing

“The Company may require additional funds to commercialize its products. The Company is unable to entirely fund these efforts with its current financial resources.” · word for word

Early-stage clinical dependency

“The company is a clinical-stage biotech with no approved products; compensation milestones are tied to clinical trial dosing and capital raising.”

Reliance on single pivotal trial for BLA; regulatory and commercial execution risks.

“Topline results expected Q3 2026; BLA submission and commercial launch planned.”

Going Concern Risk

“The Company had a net loss of $29.4 million for the year ended December 31, 2025 and an accumulated deficit of $104.5 million as of December 31, 2025, as a result of incurring losses since its inception.” · word for word

Dilution Risk

“The company conducted multiple equity offerings in 2025, including a $93.7 million underwritten public offering in December 2025.”

Potential dilution from ATM offering up to $100M; may signal cash burn or need for capital.

“Company may offer and sell shares of common stock having an aggregate offering price of up to $100,000,000.”

Clinical trial failure risk

“Clinical trials are expensive, time consuming, difficult to design and implement, and involve uncertain outcomes.” · word for word

Capital need risk

“We need significant additional financing to fund our operations and complete the development and, if approved, the commercialization of our product candidates.” · word for word

Dilution risk from equity offering

“Issuance of 19,117,646 shares and 490,196 pre-funded warrants will dilute existing shareholders.”

Cash burn risk remains high

“Company is pre-revenue biotech with accumulated deficit; raised capital to fund operations.”

Clinical trial risk remains

“Further data may not be consistent; risk of not advancing to registration-enabling studies.”

Capital need for BLA submission

“Company may need additional working capital to continue trials and submit BLA.”

Going concern risk

“Management believes that there is substantial doubt regarding the Company’s ability to continue operating as a going concern through at least the next twelve months from the date of this filing.” · word for word

Dilution risk

“The Company sold 3,915,604 shares and warrants in a private placement, and 1,087,381 shares under ATM, increasing share count significantly.”

No revenue

“The Company has not generated any revenue from product sales.”